A parkinson-like neurologic deficit in primates is caused by a novel 4-substituted piperidine
1986; Elsevier BV; Volume: 368; Issue: 2 Linguagem: Inglês
10.1016/0006-8993(86)90567-6
ISSN1872-6240
AutoresDoug Wilkening, Vernon G. Vernier, Larry Arthaud, G. Barbara Treacy, Joanne Kenney, Victor J. Nickolson, R. R. Clark, Dewey H. Smith, Chad Smith, George A. Boswell,
Tópico(s)Metabolism and Genetic Disorders
ResumoA neurologic deficit characterized by hypokinesia, postural flexion, and to a lesser extent, rigidity, tremor and myoclonus, has been observed in cynomolgus monkeys following administration of 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP), a novel 4-substituted piperidine. The syndrome, similar to that described for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), developed within 3-7 days after oral or i.v. dosing, and was accompanied by lesions in the substantia nigra. The behavioral syndrome was seen to a lesser extent in dogs but not in rats. MMPP contains a hydroxyl group on the 4-position of the pyridine ring; the corresponding dehydration product was inactive.
Referência(s)